|Biotech partner:||Ergonex Pharma (Switzerland)|
|Pharma Partner:||Pfizer (USA)|
|Type of agreement:||* commercialization/ distribution
|Compound:||terguride (oral antagonist of 5-HT2B and 5-HT2A (serotonin) receptors)|
|Disease area:||pulmonary arterial hypertension|
|Nature of the agreement:||Pfizer and Ergonex Pharma have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for pulmonary arterial hypertension (PAH).
Under the terms of the agreement, Pfizer will support the completion of the ongoing Phase II trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize terguride for the treatment of PAH.
Terguride is also currently approved in Japan for the treatment of Hyperprolactinemia.
|Financial terms of the agreement:||Ergonex will be eligible to receive undisclosed milestone payments and royalties on the sales of terguride for PAH.|